News

YM BioSciences said that the US patent numbers 7,648,981 and 7,648,982 extend the life of YM’s AeroLEF patent estate in the US to 2024. The company has also

The company will move all syrup-based product manufacturing to this facility. The facility marks Elder’s entry into injectables manufacturing, especially anti-infective products like cephalosporins. The new plant involved

Reportedly, the next data analysis is anticipated to take place during Q2 2010. StemEx is being evaluated as a therapeutic treatment for adolescents and adults with blood cancers

Transgene has employed a novel gene silencing (within RNAi platform) technology to develop this drug. The technology involves highly selective knock-down of specific liver cancer producing gene targets,

Avrio’s newly built, 20,000 square foot, aseptic fill-and-finish facility includes three aseptic suites and five production suites with each suite having its own dedicated air handling system. In

With this Agendia has obtained all major US clinical laboratory licenses with this permit. In addition, the College of American Pathologists (CAP) has accredited Agendia’s CLIA regulated laboratory

The company has informed that the US patent number: 7,659,282 titled ‘Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders’, was issued on February 9,

As claimed, the Xcelodose system can help reduce processing time and API usage in simple formulations of API or powder-in-capsule, when compared to traditional methods. Manufactured by Capsugel,

This approval represents the final national regulatory step in taking the ReN001 therapy into patients in the UK, following regulatory approval from the UK Medicines and Healthcare Products